121 related articles for article (PubMed ID: 18759214)
1. [Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)].
Maier M; Feucht N; Haas K; Fiore B; Winkler von Mohrenfels C; Clos A; Lohmann C
Klin Monbl Augenheilkd; 2008 Sep; 225(9):818-24. PubMed ID: 18759214
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
3. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
Małgorzata F
Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
[TBL] [Abstract][Full Text] [Related]
8. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
10. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
[TBL] [Abstract][Full Text] [Related]
12. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
13. [Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD)--preliminary results].
Mackiewicz J; Mańkowska A; Dolar-Szczasny J; Zubilewicz A; Oleszczuk A; Nowomiejska K; Rejdak R; Zagórski Z
Klin Oczna; 2007; 109(4-6):146-9. PubMed ID: 17725273
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
17. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
[TBL] [Abstract][Full Text] [Related]
18. [Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for occult and classic CNV in AMD].
Maier M; Haas K; Feucht N; Fiore B; Winkler von Mohrenfels C; Clos A; Lohmann C
Klin Monbl Augenheilkd; 2008 Jul; 225(7):653-9. PubMed ID: 18642209
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
20. [Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD].
Maier MM; Feucht N; Fiore B; Winkler von Mohrenfels C; Kook P; Fegert C; Lohmann C
Klin Monbl Augenheilkd; 2009 Jun; 226(6):496-502. PubMed ID: 19507101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]